ReviewCells2021
Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Relationship between metabolically unhealthy obesity and chronic obstructive pulmonary disease among U.S. adults: Evidence from NHANES 1999-2018.Clinics (Sao Paulo, Brazil) · 2026Article
- Multi-omics reveals cholesterol-driven macrophage metabolic reprogramming and inflammation in chronic obstructive pulmonary disease.Genome medicine · 2026Article
- The Association Between Stomach Disease and Chronic Obstructive Pulmonary Disease: A Cross-Sectional Analysis of the 2018 China Health and Retirement Longitudinal Study (CHARLS).International journal of chronic obstructive pulmonary disease · 2026Article
- The fatty liver index exhibits a dual association with chronic obstructive pulmonary disease: a machine learning-based analysis of two independent cohorts.Frontiers in nutrition · 2026Article
- Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction.BMJ open respiratory research · 2025Article
- Effects of Yomogi Tea on Lipid Metabolism in Renal Tubular HK-2 Cells.Foods (Basel, Switzerland) · 2025Article
- Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases.Scientific reports · 2025Article
- Lipid metabolism reprogramming in chronic obstructive pulmonary disease.Molecular medicine (Cambridge, Mass.) · 2025Review
- Association Between the Non-High-Density Lipoprotein Cholesterol-to-High-Density Lipoprotein Cholesterol Ratio (NHHR) and Mortality in Patients with COPD: Evidence From the NHANES 1999-2018.International journal of chronic obstructive pulmonary disease · 2025Article
- Hypercholesterolemia as a Causal Risk Factor for COPD: Biomarker Discovery and Therapeutic Implications From NHANES Data.International journal of chronic obstructive pulmonary disease · 2025Article
- Metabolic dysfunction-associated steatotic liver disease: an emerging comorbidity in COPD.Therapeutic advances in chronic disease · 2025Review
- Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders.Frontiers in pharmacology · 2025Review
- Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy.Life metabolism · 2024Article
- Causal relationship between Lipdome and Chronic Obstructive Pulmonary Disease and Asthma: Mendelian randomization.3 Biotech · 2024Article
- Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study.BMC pulmonary medicine · 2024Article
- The role of lipid metabolism in osteoporosis: Clinical implication and cellular mechanism.Genes & diseases · 2024Review
- Association between lipid accumulation product and chronic obstructive pulmonary disease: a cross-sectional study based on U.S. adults.Frontiers in nutrition · 2024Article
- Preserved Ratio Impaired Spirometry (PRISm): A Global Epidemiological Overview, Radiographic Characteristics, Comorbid Associations, and Differentiation from Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Review
- Advances in metabolomics of chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is currently among the most common liver diseases. Unfavorable data on the epidemiology of metabolic syndrome and obesity have increased the attention of clinicians and researchers to the problem of NAFLD. The research results allow us to emphasize the systemicity and multifactoriality of the pathogenesis of liver parenchyma lesion. At the same time, many aspects of its classification, etiology, and pathogenesis remain controversial. Local and systemic metabolic disorders are also a part of the pathogenesis of chronic obstructive pulmonary disease and can influence its course. The present article analyzes the metabolic pathways mediating the links of impaired lipid metabolism in NAFLD and chronic obstructive pulmonary disease (COPD). Free fatty acids, cholesterol, and ceramides are involved in key metabolic and inflammatory pathways underlying the pathogenesis of both diseases. Moreover, inflammation and lipid metabolism demonstrate close links in the comorbid course of NAFLD and COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.